Acquisitions (Tables)

6 Months Ended

Jun. 30, 2011

AMS [Member]

Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date

	June 17, 2011
Cash and cash equivalents	$	47,289
Commercial paper		71,000
Accounts receivable		73,868
Other receivables		791
Inventories		75,525
Prepaid expenses and other current assets		7,133
Income taxes receivable		11,179
Deferred income taxes		15,360
Property and equipment		57,372
Other intangible assets		1,390,000
Other assets		4,581
Total identifiable assets	$	1,754,098
Accounts payable	$	9,437
Accrued expenses		45,648
Deferred income taxes		507,019
Long-term debt		520,012
Other liabilities		23,578
Total liabilities assumed	$	1,105,694
Net identifiable assets acquired	$	648,404
Goodwill	$	1,752,427
Net assets acquired	$	2,400,831

Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods

	Valuation (in  millions)		Amortization Period (in years)
Customer Relationships:
Men's Health	$	97.0		17
Women's Health		49.0		15
BPH		26.0		13
Total	$	172.0		16
Developed Technology:
Men's Health	$	690.0		18
Women's Health		230.0		9
BPH		161.0		18
Total	$	1,081.0		16
In Process Research & Development:
Oracle	$	22.0		n/a
Genesis		14.0		n/a
TOPAS		8.0		n/a
Other		22.0		n/a
Total	$	66.0		n/a
Tradename:
AMS	$	59.0		n/a
GreenLight		12.0		15
Total	$	71.0		n/a
Total other intangible assets	$	1,390.0		n/a

Schedule Of Acquisition-Related Expenses

	Acquisition-related Costs		Acquisition-related Costs
	Three months ended June 30, 2011		Six months ended June 30, 2011
Bank fees	$	16,070	$	16,070
Legal, separation, integration, and other costs		5,058		7,194
Total	$	21,128	$	23,264

Schedule Of Revenue And Net Loss Of Acquiree Included In Condensed Consolidated Statements Of Operations

	Revenue and Income included in the Condensed Consolidated Statements of Operations from and including June 18, 2011 to June 30, 2011
Revenue	$	26,812
Net income attributable to Endo Pharmaceuticals Holdings Inc.	$	2,094
Basic net income per share	$	0.02
Diluted net income per share	$	0.02

Consolidated Pro Forma Results

	Three months ended June 30, 2011		Six months ended June 30, 2011
Pro forma consolidated results (in thousands, except per share data):
Revenue	$	705,119	$	1,406,013
Net income attributable to Endo Pharmaceuticals Holdings Inc.	$	14,810	$	89,740
Basic net income per share	$	0.13	$	0.77
Diluted net income per share	$	0.12	$	0.74

	Three months ended June 30, 2010		Six months ended June 30, 2010
Pro forma consolidated results (in thousands, except per share data):
Revenue	$	532,939	$	1,032,585
Net income attributable to Endo Pharmaceuticals Holdings Inc.	$	26,925	$	56,385
Basic net income per share	$	0.23	$	0.48
Diluted net income per share	$	0.23	$	0.48

Qualitest [Member]

Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date

	November 30, 2010 (As initially reported)		Measurement period adjustments			November 30, 2010 (As adjusted)
Cash and cash equivalents	$	21,828	$	—		$	21,828
Accounts receivable		93,228		—			93,228
Other receivables		1,483		—			1,483
Inventories		95,000		—			95,000
Prepaid expenses and other current assets		2,023		(121	)		1,902
Deferred income taxes		63,509		4,817			68,326
Property, Plant and equipment		135,807		—			135,807
Other intangible assets		843,000		(7,000	)		836,000
Total identifiable assets	$	1,255,878	$	(2,304	)	$	1,253,574
Accounts payable	$	27,422	$	—		$	27,422
Accrued expenses		55,210		3,466			58,676
Deferred income taxes		207,733		(2,468	)		205,265
Long-term debt		406,758		—			406,758
Other liabilities		9,370		—			9,370
Total liabilities assumed	$	706,493	$	998		$	707,491
Net identifiable assets acquired	$	549,385	$	(3,302	)	$	546,083
Goodwill	$	219,986	$	3,302		$	223,288
Net assets acquired	$	769,371	$	—		$	769,371

Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods

	Valuation (in millions)		Amortization Period (in years)
Developed Technology:
Hydrocodone and acetaminophen	$	119.0		17
Oxycodone and acetaminophen		30.0		17
Promethazine		46.0		16
Isosorbide Mononitrate ER		42.0		16
Multi Vitamins		38.0		16
Trazodone		17.0		16
Butalbital, acetaminophen, and caffeine		25.0		16
Triprevifem		16.0		13
Spironolactone		13.0		17
Hydrocortisone		34.0		16
Hydrochlorothiazide		16.0		16
Controlled Substances		52.0		16
Oral Contraceptives		8.0		13
Others		162.0		17
Total	$	618.0		16
In Process Research & Development:
Generics portfolio with anticipated 2011 launch	$	63.0		n/a
Generics portfolio with anticipated 2012 launch		30.0		n/a
Generics portfolio with anticipated 2013 launch		17.0		n/a
Generics portfolio with anticipated 2014 launch		88.0		n/a
Total	$	198.0		n/a
Tradename:
Qualitest tradename	$	20.0		15
Total	$	20.0		15
Total other intangible assets	$	836.0		n/a

Schedule Of Acquisition-Related Expenses

	Acquisition-related Costs
	Three months ended June 30, 2011		Six months ended June 30, 2011
Bank fees	$	—	$	—
Legal, separation, integration, and other costs		1,353		4,594
Total	$	1,353	$	4,594

Consolidated Pro Forma Results

	Three months ended June 30, 2010		Six months ended June 30, 2010
Pro forma consolidated results (in thousands, except per share data):
Revenue	$	481,382	$	926,193
Net income attributable to Endo Pharmaceuticals Holdings Inc.	$	50,004	$	109,787
Basic net income per share	$	0.43	$	0.94
Diluted net income per share	$	0.43	$	0.94

Penwest Pharmaceuticals Co [Member]

Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date

	September 20, 2010 (As initially reported)		Measurement period adjustments			September 20, 2010 (As adjusted)
Cash and cash equivalents	$	22,343	$	—		$	22,343
Marketable securities		800		—			800
Accounts receivable		10,885		(19	)		10,866
Other receivables		132		(1	)		131
Inventories		396		11			407
Prepaid expenses and other current assets		716		(223	)		493
Deferred income taxes		27,175		3,003			30,178
Property and equipment		1,115		(200	)		915
Other intangible assets		111,200		—			111,200
Other assets		2,104		—			2,104
Total identifiable assets	$	176,866	$	2,571		$	179,437
Accounts payable	$	229	$	—		$	229
Income taxes payable		347		(187	)		160
Penwest shareholder liability		20,815		(20,815	)		—
Accrued expenses		1,455		87			1,542
Deferred income taxes		39,951		379			40,330
Other liabilities		4,403		118			4,521
Total liabilities assumed	$	67,200	$	(20,418	)	$	46,782
Net identifiable assets acquired	$	109,666	$	22,989		$	132,655
Goodwill	$	37,952	$	1,159		$	39,111
Net assets acquired	$	147,618	$	24,148		$	171,766

Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods

	Valuation		Amortization Period (in years)
In Process Research & Development:
Otsuka	$	5.5		n/a
A0001		1.6		n/a
Total	$	7.1		n/a
Developed Technology:
Opana® ER	$	104.1		10
Total	$	104.1		10
Total other intangible assets	$	111.2		n/a

HealthTronics, Inc [Member]

Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date

	July 2, 2010 (As initially reported)			Measurement period adjustments			July 2, 2010 (As Adjusted)
Cash and cash equivalents	$	6,769		$	—		$	6,769
Accounts receivable		33,111			277			33,388
Other receivables		1,006			—			1,006
Inventories		12,399			—			12,399
Prepaid expenses and other current assets		5,204			—			5,204
Deferred income taxes		43,737			2,752			46,489
Property and equipment		30,687			—			30,687
Other intangible assets		65,866			7,258			73,124
Other assets		5,210			—			5,210
Total identifiable assets	$	203,989		$	10,287		$	214,276
Accounts payable	$	3,084		$	—		$	3,084
Accrued expenses		11,551			8,959			20,510
Deferred income taxes		20,377			1,999			22,376
Long-term debt		44,751			(1,291	)		43,460
Other liabilities		1,434			351			1,785
Total liabilities assumed	$	81,197		$	10,018		$	91,215
Net identifiable assets acquired	$	122,792		$	269		$	123,061
Noncontrolling interests	$	(60,119	)	$	(3,108	)	$	(63,227	)
Goodwill	$	152,170		$	2,839		$	155,009
Net assets acquired	$	214,843		$	—		$	214,843

Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods

	Valuation (in millions)		Amortization Period (in years)
Endocare Developed Technology	$	46.3		10
HealthTronics Tradename		14.6		15
Service Contract		12.2		n/a
Total	$	73.1		n/a

Schedule Of Acquisition-Related Expenses

	Acquisition-related Costs
	Three months ended June 30, 2011		Six months ended June 30, 2011
Bank fees	$	—	$	—
Legal, separation, integration, and other costs		1,511		2,861
Total	$	1,511	$	2,861

Consolidated Pro Forma Results

	Three months ended June 30, 2010		Six months ended June 30, 2010
Pro forma consolidated results (in thousands, except per share data):
Revenue	$	446,824	$	859,625
Net income attributable to Endo Pharmaceuticals Holdings Inc.	$	53,455	$	115,163
Basic net income per share	$	0.46	$	0.99
Diluted net income per share	$	0.46	$	0.98